Electromed (ELMD) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Electromed (ELMD) over the past year, gaining 116.3% versus a gain of 10.7%. Electromed is the larger company by market cap ($230.5 million vs $87.4 million), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELMD | NRXS |
|---|---|---|
| Share price | $27.82 | $6.96 |
| Market cap | $230.55M | $87.40M |
| 1-day change | +0.07% | +2.81% |
| YTD return | -4.53% | +49.12% |
| 1-year return | +10.67% | +116.29% |
| 5-year return | +152.96% | — |
| P/E ratio (TTM) | 21.40 | — |
| Forward P/E | 45.61 | — |
| EPS (TTM) | $1.30 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.40 | $9.33 |
| 52-week low | $23.01 | $2.21 |
| Distance from 52-week high | -41.31% | -25.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +74.34% | +58.05% |
| Average volume | 104.86K | 107.27K |
| Shares outstanding | 8.29M | 12.56M |
| Employees | 195 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Electromed is about 2.6 times larger than Neuraxis by market value ($230.55M vs $87.40M).
- NRXS has outperformed ELMD by 105.6 percentage points over the past year.
About Electromed
ELMD stock →Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 195 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
ELMD vs NRXS FAQ
Which is bigger, Electromed or Neuraxis?
Electromed (ELMD) is larger, with a market capitalization of $230.55M compared with $87.40M for Neuraxis (NRXS).
Which stock has performed better over the past year, ELMD or NRXS?
NRXS returned +116.29% over the past 12 months, compared with +10.67% for ELMD (price return, excluding dividends). Past performance does not predict future results.
Are Electromed and Neuraxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.